ONC vs. TMO: BeOne Medicines vs. Thermo Fisher Scientific Stock Comparison

Company Profile

BeOne Medicines (ONC) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Thermo Fisher Scientific (TMO) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BeOne Medicines (ONC) at 18.40% and Thermo Fisher Scientific (TMO) at 13.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both BeOne Medicines (ONC) at 13.86% and Thermo Fisher Scientific (TMO) at 14.94% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both BeOne Medicines (ONC) at 22.15% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BeOne Medicines (ONC) at 40.23% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Thermo Fisher Scientific (TMO) at 4.70 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.

Valuation Metrics